Corcept Therapeutics (CORT) CFO exercises options and sells 80,000 shares
Rhea-AI Filing Summary
Corcept Therapeutics Chief Financial Officer Mokari Atabak exercised stock options covering 80,000 shares of common stock at an exercise price of $23.06 per share on July 30, 2026, then sold 80,000 shares in multiple open-market or private transactions the same day.
The sales occurred at prices ranging from $105.305 to $120.84 per share. The option was fully exercisable and expires on February 13, 2033, with 95,833 options from this grant remaining. All reported sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 80,000 shares ($7.33M approx. pre-tax spread)
Exercise and Sale
15 txns
Insider
Mokari Atabak
Role
Chief Financial Officer
Sold
80,000 shs ($9.18M)
Approx. gross sale proceeds
$9.18M
Approx. exercise cost
$1.84M
Approx. pre-tax spread
$7.33M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) F14 | 80,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 80,000 | $23.06 | $1.84M |
| Sale | Common Stock F2, F3, F1 | 4,200 | $105.5352 | $443K |
| Sale | Common Stock F2, F4, F1 | 8,956 | $106.9553 | $958K |
| Sale | Common Stock F2, F1 | 400 | $108.46 | $43K |
| Sale | Common Stock F2, F5, F1 | 2,202 | $110.0283 | $242K |
| Sale | Common Stock F2, F1 | 600 | $110.95 | $67K |
| Sale | Common Stock F2, F6, F1 | 4,700 | $113.1789 | $532K |
| Sale | Common Stock F2, F7, F1 | 15,477 | $114.9601 | $1.78M |
| Sale | Common Stock F2, F8, F1 | 14,222 | $115.8669 | $1.65M |
| Sale | Common Stock F2, F9, F1 | 7,089 | $116.9561 | $829K |
| Sale | Common Stock F2, F10, F1 | 8,267 | $117.9329 | $975K |
| Sale | Common Stock F2, F11, F1 | 4,783 | $118.7346 | $568K |
| Sale | Common Stock F2, F12, F1 | 8,103 | $119.9481 | $972K |
| Sale | Common Stock F2, F13, F1 | 1,001 | $120.6749 | $121K |
Holdings After Transaction:
Stock option (right to buy) — 95,833 shares (Direct);
Common Stock — 16,130 shares (Direct)
Footnotes (14)
- F1. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
- F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $105.305 to $106.2 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $106.75 to $107.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.71 to $110.42 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F6. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.96 to $113.89 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F7. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.305 to $115.30 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F8. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.35 to $116.27 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F9. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.35 to $117.3 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F10. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.41 to $118.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F11. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.42 to $119.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F12. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.42 to $120.41 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F13. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $120.49 to $120.84 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F14. Fully exercisable.
Key Figures
Options Exercised: 80,000 shares
Exercise Price: $23.06 per share
Shares Sold: 80,000 shares
+5 more
8 metrics
Options Exercised
80,000 shares
Stock options for common stock exercised on July 30, 2026
Exercise Price
$23.06 per share
Exercise price of stock options converted into common stock
Shares Sold
80,000 shares
Common shares sold in multiple transactions on July 30, 2026
Sale Price Range Low
$105.305 per share
Lowest actual sale price across weighted-average sale groups
Sale Price Range High
$120.84 per share
Highest actual sale price across weighted-average sale groups
Options Remaining
95,833 options
Stock options of this grant owned following the reported exercise
Option Expiration
February 13, 2033
Expiration date of the exercised stock option grant
10b5-1 Plan Adoption Date
December 12, 2025
Date Rule 10b5-1 trading plan was adopted by the reporting person
Key Terms
Rule 10b5-1 plan, weighted average sale price, restricted stock awards, stock option (right to buy)
4 terms
Rule 10b5-1 plan regulatory
"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"Represents the weighted average sale price for the entire number of shares sold"
restricted stock awards financial
"Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
stock option (right to buy) financial
"security_title: Stock option (right to buy) reported as a derivative security"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Corcept Therapeutics (CORT) CFO Mokari Atabak report?
Mokari Atabak reported exercising stock options for 80,000 shares of Corcept Therapeutics common stock at $23.06 per share, then selling 80,000 shares in multiple open-market or private transactions on July 30, 2026, under a preset Rule 10b5-1 trading plan.
What stock options did the Corcept (CORT) CFO exercise in this report?
He exercised a fully exercisable stock option for 80,000 shares of Corcept common stock at an exercise price of $23.06 per share. The option expires on February 13, 2033, and following the exercise, 95,833 options from this grant remain outstanding.
What restricted stock awards are referenced for the Corcept (CORT) CFO?
Footnotes reference unvested restricted stock awards totaling several small grants: 200 shares (September 2, 2025), 178 shares (December 1, 2025), 397 shares (March 2, 2026), and 634 shares (June 1, 2026). Each grant vests 100% on its one-year anniversary if specified conditions are met.
What is the remaining option position after the Corcept (CORT) CFO’s exercise?
After exercising options for 80,000 shares, the reporting person holds 95,833 stock options from this grant. These options are reported as fully exercisable and carry an expiration date of February 13, 2033, providing ongoing potential to acquire additional Corcept common shares.